Antioxidant Effect of Thioredoxin and Vitamin D3 in Peritoneal Dialysis Patients

Basit Öğe Kaydı
dc.authoridBakirdogen, Serkan/0000-0002-3448-0490
dc.authorid, Sara/0000-0002-9618-7521
dc.contributor.authorIleri, Sara Yavuz
dc.contributor.authorBatman, Adnan
dc.contributor.authorEraldemir, Ceyla
dc.contributor.authorBakirdogen, Serkan
dc.contributor.authorDervisoglu, Erkan
dc.date.accessioned2025-01-27T20:49:42Z
dc.date.available2025-01-27T20:49:42Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground. Among the chronic diseases, chronic kidney failure is one of diseases that have the most difficulty in coping with oxidative stress due to the deterioration of the antioxidant system balance in the body. Beyond being a vitamin, 1 alpha,25-dihydroxycholecalciferol (vitamin D3) is a molecule that positively or negatively affects many enzymes which are in protein structures. Thioredoxin (TRX), which has an important role in the antioxidant system, is one of these proteins. By conducting this study, we wanted to emphasize the role of vitamin D3 in reducing the oxidative stress load on patients undergoing peritoneal dialysis (PD) via serum TRX level measurement. Methods. In this study, we evaluated the medical treatments of 69 PD patients who were followed up routinely. The patients were divided into 2 groups according to whether they used vitamin D3 or not. 49 of our patients were using vitamin D3. While requesting routine laboratory tests, we reserved a separate serum sample to measure serum TRX levels by double-antibody sandwich enzyme-linked immunosorbent assay for all patients. Results. Only one parameter has a significant statistical relationship with serum TRX level and the treatment protocol. The serum TRX level was significantly higher (211,62 U/l +/- 314,46) in the group receiving vitamin D3 compared to the group which is not using Vitamin D3 (101,63 U/l +/- 215,03) (p < 0,006). Conclusion. This study highlights the importance of appropriate dose of vitamin D3 replacement especially in PD patients who are under intense oxidative stress compared to healthy individuals.
dc.identifier.doi10.1155/2022/2590944
dc.identifier.issn2314-6133
dc.identifier.issn2314-6141
dc.identifier.pmid35547357
dc.identifier.scopus2-s2.0-85130397736
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1155/2022/2590944
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25284
dc.identifier.volume2022
dc.identifier.wosWOS:000802856500002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofBiomed Research International
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectOxidative Stress
dc.subjectErythropoietin
dc.subjectTarget
dc.titleAntioxidant Effect of Thioredoxin and Vitamin D3 in Peritoneal Dialysis Patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu